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Erdheim-Chester disease (ECD) is a rare non-Langerhan’s cell histiocytosis of unknown origin, involving
multiple organs. The patient with ECD described here is a 38-year-old man who was admitted to the
hospital with dyspnea on exertion. His chest radiograph revealed a diffuse reticulonodular shadow. After
the video-assisted thoracoscopic surgery was performed, he was diagnosed as having ECD. A brown
eruption on his left temple, when tested by skin biopsy, proved to be ECD. No lesions other than these on
the lung and skin were identiﬁed, and oral administration of predonisolone successfully treated both of
them. Although recovery has followed the administration of predonisolone and chemotherapy for
several patients with pulmonary ECD, this is the ﬁrst report that predonisolone alone provided clinical
and objective recovery from pulmonary ECD. This outcome indicates that, of all the many treatments
tried for ECD, steroids may become the ﬁrst-line therapy for pulmonary involvement.
 2010 Elsevier Ltd. All rights reserved.1. Introduction
Erdheim-Chester disease (ECD), which was ﬁrst described by
William Chester in 1930,1,2 still has no known cause. The most
commonly affected organs in ECD are the long bones, but more than
50% of the patients suffer extraskeletal involvements, including
orbits, pituitary glands, retroperitoneal spaces, skin, lungs, kidneys
and hearts.1,3,4 The prognosis of this disease is often poor when
extraskeletal pathology results in cardiomyopathy, respiratory or
renal failure and central nerve involvement.2,5,6 Various treatments
have been tried, such as corticosteroids, interferon, chemotherapy
(cyclophosphamide, vinblastine, adriamycin, etoposide, etc.), cyclo-
sporine, radiotherapy and surgical resection.1,7,8 However, no stan-
dard treatment for ECDhasbeenestablishedasyet. In addition, owing
to the rarity of ECD patients whose organ involvement is limited
mainly to the lungs, few treatments for pulmonary ECD have been
reported in the literature. Accordingly, neither the most effective
therapy for pulmonary involvement nor which type should be initi-
ated ﬁrst has been established.
In this report, we describe a 38-year-old man with ECD limited
mainly to the lungs. Oral administration of predonisolone relieved: þ81 3 5802 1617.
ahama).
rved.dyspnea on exertion and improved pulmonary function as docu-
mented in radiological ﬁndings. This successful outcome suggests
that steroid is an effective ﬁrst-line treatment for early-phase
pulmonary ECD.
2. Case report
A 38-year-old man undergoing his regular health examination
in July 2007 had a chest radiograph that showed an abnormal
shadow. Within a few months, he began to feel dyspnea that
gradually worsened on exertion. He was admitted to our hospital
for evaluation on April 2008. His history noted that he worked as
a plumber and had smoked 30 cigarettes daily for 20 years until he
stopped because of the dyspnea. The only abnormality recorded
during his physical examination was a brown swollen eruption on
the temple (Fig. 1A). However, the chest radiograph showed diffuse
reticulonodular shadows that were distributed principally in the
bilateral lower lung ﬁelds (Fig. 2A). Computerized tomography (CT)
of the patient’s chest revealed thickening of the pleura, interlobular
septa and peribronchovascular interstitial markings as well as ﬁne
nodules and small cysts scattered predominantly in the bilateral
lower lobes (Fig. 2B,C). No swelling of lymph nodes was evident in
the mediastinum. Laboratory tests showed a slight elevation in
C-reactive protein (0.6 mg/dL) and soluble IL-2 receptor (925 U/
mL). Arterial blood gas analysis was normal. The pulmonary func-
tion tests showed reductions in vital capacity (VC) of 3.1 L (75.1% of
Fig. 1. Skin involvement identiﬁed in the left temple. Brown maculae and elastic hard eruption were identiﬁed on the left temple prior to the administration of predonisolone (A).
The lesion gradually softened and ﬂattened within several months after the initiation of predonisolone treatment (B). Fig. 1B is a matching photo taken a year and two months after
the treatment began.
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(68.1% of the predicted) and diffusing capacity for carbonmonoxide
(DLCO) of 11.1 mL/min/mmHg (39.9% of the predicted). His 6-min
walking test revealed the desaturation of SpO2 from 96% to 88%
with a substantial walking distance of 427 m.
Sarcoidosis, chronic hypersensitive pneumonia, Langerhans’ cell
histiocytosis and lymphoproliferative disorder were considered as
differential diagnoses. Bronchoalveolar lavage ﬂuid contained an
increasedpercentage of lymphocytes (28%) andanelevatedCD4/CD8
ratio (6.3). Transbronchial lung biopsy was performed twice, but theFig. 2. Radiologic ﬁndings in the lungs. Chest radiograph taken on the admission showed a
and a thickening of a minor ﬁssure line in the right lung (A). The thickening of interstitial m
bilateral lower lobes (B), representative image of the lower lung ﬁeld. The chest CT taken 4 m
the thickening of interstitial markings and interlobular septa had lessened, and the ﬁne nohistopathological examination of a tissue specimen showed only
a slight increase of collagenﬁbers inpart of the alveolarwall. Because
sarcoidosis was suspected, a skin biopsy of the brown eruptions on
the left temple was performed; xanthomatous changes were found
but no evidence of epithelioid cell granuloma. To complete the
diagnosis, video-assisted thoracoscopic surgery was performed.
Subsequent histopathological examination revealed ﬁbrous thick-
enings of the pleura and the interlobular septa along with marked
inﬁltration of foamy histiocytes in the ﬁbrotic areas (Fig. 3A). Elastica
van Gieson staining of the resected specimen demonstrated thatdiffuse reticulonodular pattern predominantly distributed in bilateral lower lung ﬁelds
arkings and interlobular septa, ﬁne nodules and small cysts scattering dominantly in
onths after the initiation of an oral administration of predonisolone demonstrated that
dules had disappeared. (C), representative image of the lower lung ﬁeld.
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Fig. 4. Improvement of pulmonary function after the initiation of predonisolone.
Abbreviations used are: %VC, vital capacity % of the predicted value; and %DLCO,
diffusing capacity for carbon monoxide % of the predicted value.
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and been replaced with collagen ﬁbers (not shown). Immunohisto-
chemical investigation showed that these foamy histiocytes were
positive for CD68 (Fig. 3B) and Factor XIIIa (not shown), and positive
for S100 (Fig. 3C) in some areas, but negative for CD1a (Fig. 3D).
Serum IL-6 level was demonstrated to increase to 5.8 pg/ml (normal
range, <4.0 pg/mL).
A diagnosis of ECD was made based on these histopathological
ﬁndings and conﬁrmed after re-evaluation of a skin specimen from
the left temple proved its involvement. No clinical ﬁndings other
than those of the lung and the skin were noted.
The patient’s treatment began with an oral administration of
predonisolone, initially 30 mg/day and gradually reduced to 5 mg/
day over a period of about two years (Fig. 4). After 2 months of
predonisolone administration, the patient’s dyspnea on exertion
signiﬁcantly decreased, i.e., the oxygen cost diagram increased
from 54 mm to 82 mm (not shown) and the desaturation dis-
appeared. He has since been virtually free from symptoms. CTof the
chest 4 months after this treatment revealed that the former
thickening of the interlobar septa and perivascular interstitial
markings decreased and that the small nodules disappeared
(Fig. 2C). His serum IL-6 level dropped to 0.9 pg/mL. Additionally,
the xanthogranuloma of the left temple became softer and ﬂatter
(Fig. 1B). Similarly, the patient’s restrictive ventilatory impairment
and the impaired diffusing capacity improved, but the course was
slower requiring over a year after predonisolone treatment began
(Fig. 4).3. Discussion
The patient described here is unique, because he represents
a rare case of ECD limited mainly to the lungs. ECD, althoughFig. 3. Histopathological ﬁndings for the lung specimen resected by video-assisted thorac
histiocytes and scattered Touton giant cells (A, original magniﬁcation 100). Immunohistoch
positive for S100 (C), but negative for CD1a (D) (B e D, original magniﬁcation 400).uncommon, usually afﬂicts middle-aged and older adults, with
slight predominance in males.5,9 ECD often involves multiple
organs, but one of the most common symptoms of this disease is
bone pain.5 Only approximately 35% of these patients experience
pulmonary involvement,1 and those with lesions only in the lungs
are far fewer.1,2,5,7,9,10 However, pulmonary ECD has a particularly
poor prognosis, since the overall 3-year survival rate is only 66%.
To establish the diagnosis of pulmonary ECD, it is important for
pulmonologists to document the occurrence of ECD limited entirely
or mostly to the lungs. Radiologic examination is essential for
establishing pulmonary exclusivity for ECD. On a chest radiograph,
interstitial inﬁltrates should be visible distributed predominantlyoscopic surgery. Hematoxylin-eosin staining revealed a diffuse proliferation of foamy
emistry demonstrated that foamy histiocytes were strongly positive for CD68 (B), partly
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lution imaging, is likely to reveal thickening of the interlobular
septa, pleura, and peribronchovascular interstitium.11 Judging from
these criteria, the radiologic ﬁndings of our patient were indeed
characteristic of ECD and not compatible with those of Langerhans
cell histiocyte disease. Histopathologic examinations, especially
immunohistochemical evaluation, are required to prove the
proliferation of non-Langerhans cell histocytes. In the case of our
patient described here, the proliferating histiocytes were indeed
positive for CD68, negative for CD1a, and in some instances
immunoreactive for S100. Biopsy of skin on the patient’s left
temple, which was performed because of suspected sarcoidosis,
was ﬁrst interpreted as xanthomatous changes. However, re-eval-
uation after the diagnosis of ECD by lung biopsy proved to include
involvement of the patient’s skin. The skin biopsy might have been
sufﬁcient for that diagnosis if the inclusion of lungs and skin were
more often recognized as markers of this rare disease along with
non-Langerhans histiocytes.
The most effective treatment for ECD has not yet been estab-
lished, since the number of such patients is so small, but several
published studies include sites other than the heart and lungs.
Regarding therapeutic options, corticosteroid is the traditional
ﬁrst-line treatment to control symptoms, either used alone or
combined with other agents such as cyclophosphamide or
etoposide.11e16 Veyssier-Belt et al. described one patient whose ECD
included skeletal pain and exophthalmos and another with renal,
skeletal and liver involvement improved by corticosteroid alone.2
They also cited amelioration of symptoms in the bones and brain
as well as exophthalamos after administering radiotherapy either
alone or combined with corticosteroids or chemotherapy.2 Else-
where, interferon-a appeared to be effective for exophthalamos,
bilateral hydronephrosis, xanthelasma and periaortic ﬁbrosis
involving the whole aorta.17,18 To date, 44 reports of ECD with
pulmonary involvement have been published, but none of those
patients improved objectively and some died of respiratory failure
when treated solely with corticosteroids.2,16,19,20 Only one patient
with ECD and multiple organ involvement including the lungs has
exhibited some recovery after treatment with corticosteroid
alone.12 Two groups have reported the improvement or stabiliza-
tion of disease condition after combining cyclophosphamide and
corticosteroid, although the latter drug alone slowed the progres-
sive course of pulmonary failure.7,10 In contrast to these previous
reports,2,12,16,19,20 our patient showed signiﬁcant lessening of
symptoms, and improved scores in pulmonary function tests,
radiologic ﬁndings of the chest and serum content of IL-6 after
receiving predonisolone alone. A present, two years have passed
since the patient began taking oral predonisolone, and this treat-
ment has controlled his ECD well. The striking difference between
this patient and others may be the severity of lung involvement.
Our patient’s ECD may have been at an extremely early stage of
development, since it was incidentally identiﬁed as mildly
impaired pulmonary function during a routine annual medical
checkup.
In conclusion, this is the ﬁrst documented report of ECD with
lesions limited primarily to the lungs and virtually expunged with
predonisolone treatment alone. This outcome may indicate that
predonisolone is a preferred treatment for pulmonary ECD, espe-
cially at a stage of mild functional impairment.Conﬂict of interest statement
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